Oral glucose lowering with linagliptin and metformin compared with linagliptin alone as initial treatment in Asian patients with newly diagnosed type 2 diabetes and marked hyperglycemia: Subgroup analysis of a randomized clinical trial

AIMS/INTRODUCTION: Type 2 diabetes mellitus is an epidemic in Asia, yet clinical trials of glucose‐lowering therapies often enroll predominantly Western populations. We explored the initial combination of metformin and linagliptin, a dipeptidyl peptidase‐4 inhibitor, in newly diagnosed type 2 diabet...

Descripción completa

Detalles Bibliográficos
Autores principales: Ma, Ronald CW, Del Prato, Stefano, Gallwitz, Baptist, Shivane, Vyankatesh K, Lewis‐D'Agostino, Diane, Bailes, Zelie, Patel, Sanjay, Lee, Jisoo, von Eynatten, Maximilian, Di Domenico, Maximiliano, Ross, Stuart A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5934255/
https://www.ncbi.nlm.nih.gov/pubmed/28921919
http://dx.doi.org/10.1111/jdi.12746

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5934255/
https://www.ncbi.nlm.nih.gov/pubmed/28921919
http://dx.doi.org/10.1111/jdi.12746

Ejemplares similares